iCo Therapeutics Inc.
iCo Therapeutics Inc.
- ISIN: CA45107J1057
- Land: .
Nachricht vom 15.06.2017 | 22:15
iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017.
Stated Andrew Rae, CEO of iCo Therapeutics, 'we are excited to have arrived at this inflection point with our colleagues at Salvat and look forward to important guidance regarding a clinical path forward for a potential first in class glaucoma candidate'.
For more information please refer to:
Laboratorios SALVAT is a privately owned pharmaceutical group closely identified with technological innovation and strongly committed to R&D. SALVAT's headquartered are located in Barcelona (Spain) and its US subsidiary, SALVAT USA, is located in Miami, FL. Founded in 1955, SALVAT is present in over 60 countries and keeps strengthening its international presence through the licensing of its own developments. The company launched CETRAXAL® (ciprofloxacin 0.2 %) otic solution in the US in 2009 and received FDA approval for OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution in April 2016.
Additional information regarding Laboratorios SALVAT and its products is available at www.salvatbiotech.com
About iCo Therapeutics
iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company's core focus areas and if so the Company will seek to capture further value via partnerships, such as its partnership with Immune Pharmaceuticals (NASDAQ: IMNP), which is in several Phase 2 studies involving iCo-008. iCo shares trade on the TSX Venture Exchange under the symbol 'ICO' and on the OTCQB under the symbol 'ICOTF'.
For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking statements' within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will,' and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/27456
|Company:||iCo Therapeutics Inc.|
|End of News||DGAP News Service|
GBC im Fokus
M1 Kliniken AG: Kursziel angehoben
Die M1 Kliniken AG hat den eingeschlagenen Wachstumskurs mit einem Umsatzanstieg von 20,3 % auch im ersten Halbjahr fortgesetzt. Analog dazu gelang es der Gesellschaft, einen überproportionalen Anstieg des EBIT um 36,5% zu erreichen und unsere Erwartungen zu übertreffen. Wir haben auf dieser Grundlage unsere Umsatz- und Ergebnisschätzungen angehoben. Bei einem Kursziel von 16,15 € ergibt sich ein hohes Kurspotenzial - damit lautet das Rating KAUFEN.
Der AKTIONÄR News
18. Oktober 13:42 BB-Biotech-Beteiligung Novo Nordisk: Spannung vor US-Treffen, Aktie ...
18. Oktober 13:20 Infineon hat noch Luft nach oben
18. Oktober 12:14 Intel stellt neuen KI-Prozessor vor
18. Oktober 08:56 Dow Jones auf Rekordfahrt: Das sind jetzt die Top-Tipps der Analysten
18. Oktober 08:55 Nächster Meilenstein: Dow Jones erstmals bei 23.000 Punkten
News im Fokus
Vonovia SE: Vonovia und die französische Groupe SNI unterzeichnen Partnerschaftsvereinbarung (News mit Zusatzmaterial)
18. Oktober 2017, 12:50
Memorandum of Understanding Signed with France’s Largest Residential Landlord Société Nationale Immobilière (SNI)
18. Oktober 2017
Original-Research: Bonterra Resources Inc. (von GOLDINVEST Consulting GmbH): Spekulativ Kaufen
18. Oktober 2017